Identification of Secretaglobin Scgb2a1 as a target for developmental reprogramming by BPA in the rat prostate

Epigenetics

Volumn 10, Issue 2, 2015, Pages 127-134

  Wong, Rebecca Lee Yean ^a   Wang, Quan ^a   Treviño, Lindsey S ^a   Bosland, Maarten C ^b   Chen, Jing ^c   Medvedovic, Mario ^c   Prins, Gail S ^b   Kannan, Kurunthachalam ^d   Ho, Shuk Mei ^c   Walker, Cheryl Lyn ^a  

^a TEXAS A AND M HEALTH SCIENCE CENTER   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^c UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^d STATE UNIVERSITY OF NEW YORK   (United States)

Author keywords

BPA; Developmental reprogramming; DNA methylation; Prostate cancer; Prostatein; Scgb2a1

Indexed keywords

4, 4' ISOPROPYLIDENEDIPHENOL; H3K9AC; MAMMAGLOBIN B; PROTEIN; UNCLASSIFIED DRUG; 4,4' ISOPROPYLIDENEDIPHENOL; BENZHYDRYL DERIVATIVE; ESTROGEN; HISTONE; LYSINE; PHENOL DERIVATIVE; SCGB2A1 PROTEIN, RAT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER RISK; CHROMATIN IMMUNOPRECIPITATION; CPG ISLAND; DNA METHYLATION; DRUG BLOOD LEVEL; DYSPLASIA; GENE; GENE EXPRESSION; HYPERPLASIA; INFLAMMATION; MALE; NEWBORN; NONHUMAN; NUCLEAR REPROGRAMMING; PRECANCER; PROSTATE; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ISOLATION; RNA SEQUENCE; SCGB2A1 GENE; ACETYLATION; ANIMAL; CHEMICALLY INDUCED; DRUG EFFECTS; GROWTH, DEVELOPMENT AND AGING; METABOLISM; PROMOTER REGION; PROSTATE HYPERTROPHY; SPRAGUE DAWLEY RAT; UPREGULATION;

RATTUS;

ACETYLATION; ANIMALS; ANIMALS, NEWBORN; BENZHYDRYL COMPOUNDS; CELLULAR REPROGRAMMING; CPG ISLANDS; DNA METHYLATION; ESTROGENS, NON-STEROIDAL; HISTONES; LYSINE; MALE; MAMMAGLOBIN B; PHENOLS; PROMOTER REGIONS, GENETIC; PROSTATE; PROSTATIC HYPERPLASIA; RATS, SPRAGUE-DAWLEY; UP-REGULATION;

EID: 84924980787     PISSN: 15592294     EISSN: 15592308     Source Type: Journal    
DOI: 10.1080/15592294.2015.1009768     Document Type: Article

References (52)

1. Henley DV, Korach KS. Endocrine-disrupting chemicals use distinct mechanisms of action to modulate endocrine system function. Endocrinology 2006; 147: S25-32; PMID:16690802; http://dx.doi.org/10.1210/en.2005-1117
2. Welshons WV, Thayer KA, Judy BM, Taylor JA, Curran EM, vom Saal FS. Large effects from small exposures. I. Mechanisms for endocrine-disrupting chemicals with estrogenic activity. Environ Health Perspect 2003; 111:994-1006; PMID:12826473; http://dx.doi.org/10.1289/ehp.5494.
3. Mileva G, Baker SL, Konkle AT, Bielajew C. Bisphenol-A: epigenetic reprogramming and effects on reproduction and behavior. Int J Environ Res Public Health 2014; 11:7537-61; PMID:25054232; http://dx.doi.org/10.3390/ijerph110707537
4. Rochester JR. Bisphenol A and Human Health: A review of the literature. Reprod Toxicol 2013; 42:132-55; PMID:23994667
5. Calafat AM, Kuklenyik Z, Reidy JA, Caudill SP, Ekong J, Needham LL. Urinary concentrations of bisphenol A and 4-nonylphenol in a human reference population. Environ Health Perspect 2005; 113:391-5; PMID:15811827; http://dx.doi.org/10.1289/ehp.7534
6. Calafat AM, Ye X, Wong LY, Reidy JA, Needham LL. Exposure of the US population to bisphenol A and 4-tertiary-octylphenol: 2003-2004. Environ Health Perspect 2008; 116:39-44; PMID:18197297; http://dx.doi.org/10.1289/ehp.10753
7. Wetherill YB, Petre CE, Monk KR, Puga A, Knudsen KE. The xenoestrogen bisphenol A induces inappropriate androgen receptor activation and mitogenesis in prostatic adenocarcinoma cells. Mol Cancer Ther 2002; 1:515-24; PMID:12479269
8. Wetherill YB, Fisher NL, Staubach A, Danielsen M, de Vere White RW, Knudsen KE. Xenoestrogen action in prostate cancer: pleiotropic effects dependent on androgen receptor status. Cancer Res 2005; 65:54-65; PMID:15665279
9. Wetherill YB, Hess-Wilson JK, Comstock CE, Shah SA, Buncher CR, Sallans L, Limbach PA, Schwemberger S, Babcock GF, Knudsen KE. Bisphenol A facilitates bypass of androgen ablation therapy in prostate cancer. Mol Cancer Ther 2006; 5:3181-90; PMID:17172422; http://dx.doi.org/10.1158/1535-7163.MCT-06-0272
10. Derouiche S, Warnier M, Mariot P, Gosset P, Mauroy B, Bonnal JL, Slomianny C, Delcourt P, Prevarskaya N, Roudbaraki M. Bisphenol A stimulates human prostate cancer cell migration remodelling of calcium signalling. SpringerPlus 2013; 2:54; PMID:23450760; http://dx.doi.org/10.1186/2193-1801-2-54
11. Tarapore P, Ying J, Ouyang B, Burke B, Bracken B, Ho SM. Exposure to bisphenol A correlates with earlyonset prostate cancer and promotes centrosome amplification and anchorage-independent growth in vitro. PloS one 2014; 9:e90332; PMID:24594937; http://dx.doi.org/10.1371/journal.pone.0090332
12. Ho SM, Tang WY, Belmonte de Frausto J, Prins GS. Developmental exposure to estradiol and bisphenol A increases susceptibility to prostate carcinogenesis and epigenetically regulates phosphodiesterase type 4 variant 4. Cancer Res 2006; 66:5624-32; PMID:16740699; http://dx.doi.org/10.1158/0008-5472.CAN-06-0516
13. Prins GS, Ye SH, Birch L, Ho SM, Kannan K. Serum bisphenol A pharmacokinetics and prostate neoplastic responses following oral and subcutaneous exposures in neonatal Sprague-Dawley rats. Reprod Toxicol 2011; 31:1-9; PMID:20887781; http://dx.doi.org/10.1016/j.reprotox.2010.09.009
14. Parker M, Needham M, White R. Prostatic steroid binding protein: gene duplication and steroid binding. Nature 1982; 298:92-4; PMID:6896362; http://dx.doi.org/10.1038/298092a0
15. Lea OA, Petrusz P, French FS. Prostatein. A major secretory protein of the rat ventral prostate. J Biol Chem 1979; 254:6196-202; PMID:447706
16. Mukherjee AB, Ulane RE, Agrawal AK. Role of uteroglobin and transglutaminase in masking the antigenicity of implanting rabbit embryos. Am J Reprod Immunol 1982; 2:135-41; PMID:6126131; http://dx.doi.org/10.1111/j.1600-0897.1982.tb00154.x
17. Mukherjee A, Chakrabarti J, Chakrabarti A, Banerjee T, Sarma A. Effect of ’Pan Masala’ on the germ cells of male mice. Cancer Lett 1991; 58:161-5; PMID:1855192; http://dx.doi.org/10.1016/0304-3835(91)90095-Y
18. Maccioni M, Riera CM, Rivero VE. Identification of rat prostatic steroid binding protein (PSBP) as an immunosuppressive factor. J Reprod Immunol 2001; 50:133-49; PMID:11334995; http://dx.doi.org/10.1016/S0165-0378(01)00060-2
19. Carter DB, Resnick MI. High resolution analysis of human prostatic fluid by two-dimensional electrophoresis. Prostate 1982; 3:27-33; PMID:6176986; http://dx.doi.org/10.1002/pros.2990030106
20. Lehrer RI, Xu G, Abduragimov A, Dinh NN, Qu XD, Martin D, Glasgow BJ. Lipophilin, a novel heterodimeric protein of human tears. FEBS Letters 1998; 432:163-7; PMID:9720917; http://dx.doi.org/10.1016/S0014-5793(98)00852-7
21. Becker RM, Darrow C, Zimonjic DB, Popescu NC, Watson MA, Fleming TP. Identification of mammaglobin B, a novel member of the uteroglobin gene family. Genomics 1998; 54:70-8; PMID:9806831; http://dx.doi.org/10.1006/geno.1998.5539
22. Zhao C, Nguyen T, Yusifov T, Glasgow BJ, Lehrer RI. Lipophilins: human peptides homologous to rat prostatein. Biochem Biophys Res Commun 1999; 256:147-55; PMID:10066439; http://dx.doi.org/10.1006/bbrc.1999.0274
23. Fluchter SH, Nelde HJ, Bjork P, Muntzing J, Bichler KH. Effect of treatment on the expression of estramustine-binding protein (EMBP) in prostatic cancer patients: an immunohistochemical study. Prostate 1989; 14:27-43; PMID:2648345; http://dx.doi.org/10.1002/pros.2990140105
24. Bosland MC, Ford H, Horton L. Induction at high incidence of ductal prostate adenocarcinomas in NBL/Cr and Sprague-Dawley Hsd:SD rats treated with a combination of testosterone and estradiol-17 b or diethylstilbestrol. Carcinogenesis 1995; 16:1311-7; PMID:7788848; http://dx.doi.org/10.1093/carcin/16.6.1311
25. Ofner P, Bosland MC, Vena RL. Differential effects of diethylstilbestrol and estradiol-17 b in combination with testosterone on rat prostate lobes. Toxicol Appl Pharmacol 1992; 112:300-9; PMID:1539166; http://dx.doi.org/10.1016/0041-008X(92)90200-C
26. Bernoulli J, Yatkin E, Laakso A, Anttinen M, Bosland M, Vega K, Kallajoki M, Santti R, Pylkkanen L. Histopathological evidence for an association of inflammation with ductal pin-like lesions but not with ductal adenocarcinoma in the prostate of the noble rat. Prostate 2008; 68:728-39; PMID:18302197; http://dx.doi.org/10.1002/pros.20719
27. Chughtai B, Lee R, Te A, Kaplan S. Role of inflammation in benign prostatic hyperplasia. Rev Urol 2011; 13:147-50; PMID:22110398
28. Sfanos KS, De Marzo AM. Prostate cancer and inflammation: the evidence. Histopathology 2012; 60:199-215; PMID:22212087; http://dx.doi.org/10.1111/j.1365-2559.2011.04033.x
29. Hayashi N, Sugimura Y, Kawamura J, Donjacour AA, Cunha GR. Morphological and functional heterogeneity in the rat prostatic gland. Biol Reprod 1991; 45:308-21; PMID:1786296; http://dx.doi.org/10.1095/biolreprod45.2.308
30. Huang L, Pu Y, Alam S, Birch L, Prins GS. The role of Fgf10 signaling in branching morphogenesis and gene expression of the rat prostate gland: lobe-specific suppression by neonatal estrogens. Dev Biol 2005; 278:396-414; PMID:15680359; http://dx.doi.org/10.1016/j.ydbio.2004.11.020
31. Suzuki T, Fujimoto N, Kitamura S, Ohta S. Quantitative determination of lobe specificity of mRNA expression of androgen-dependent genes in the rat prostate gland. Endocr J 2007; 54:123-32; PMID:17146147; http://dx.doi.org/10.1507/endocrj.K06-142
32. Banerjee PP, Banerjee S, Brown TR. Increased androgen receptor expression correlates with development of age-dependent, lobe-specific spontaneous hyperplasia of the brown Norway rat prostate. Endocrinology 2001; 142:4066-75; PMID:11517186; http://dx.doi.org/10.1210/endo.142.9.8376
33. Li LC, Dahiva R. MethPrimer: desiging primers for methylation PCRs. Bioinformatics 2002; 18:1427-31; PMID:12424112; http://dx.doi.org/10.1093/bioinformatics/18.11.1427
34. Claessens F, Rushmere NK, Davies P, Celis L, Peeters B, Rombauts WA. Sequence-specific binding of androgen-receptor complexes to prostatic binding protein genes. Mol Cell Endocrinol 1990; 74:203-12; PMID:2095354; http://dx.doi.org/10.1016/0303-7207(90)90225-W
35. Adib TR, Henderson S, Perrett C, Hewitt D, Bourmpoulia D, Ledermann J, Boshoff C. Predicting biomarkers for ovarian cancer using gene-expression microarrays. Br J Cancer 2004; 90:686-92; PMID:14760385; http://dx.doi.org/10.1038/sj.bjc.6601603
36. Tassi RA, Bignotti E, Rossi E, Falchetti M, Donzelli C, Calza S, Ravaggi A, Bandiera E, Pecorelli S, Santin AD. Overexpression of mammaglobin B in epithelial ovarian carcinomas. Gynecol Oncol 2007; 105:578-85; PMID:17343903; http://dx.doi.org/10.1016/j.ygyno.2007.01.043
37. Tassi RA, Calza S, Ravaggi A, Bignotti E, Odicino FE, Tognon G, Donzelli C, Falchetti M, Rossi E, Todeschini P, et al. Mammaglobin B is an independent prognostic marker in epithelial ovarian cancer and its expression is associated with reduced risk of disease recurrence. BMC Cancer 2009; 9:253; PMID:19635143; http://dx.doi.org/10.1186/1471-2407-9-253
38. Bellone S, Tassi R, Betti M, English D, Cocco E, Gasparrini S, Bortolomai I, Black JD, Todeschini P, Romani C, et al. Mammaglobin B (SCGB2A1) is a novel tumour antigen highly differentially expressed in all major histological types of ovarian cancer: implications for ovarian cancer immunotherapy. Br J Cancer 2013; 109:462-71; PMID:23807163; http://dx.doi.org/10.1038/bjc.2013.315
39. Tassi RA, Bignotti E, Falchetti M, Calza S, Ravaggi A, Rossi E, Martinelli F, Bandiera E, Pecorelli S, Santin AD. Mammaglobin B expression in human endometrial cancer. Int J Gynecol Cancer 2008; 18:1090-6; PMID:18021217; http://dx.doi.org/10.1111/j.1525-1438.2007.01137.x
40. Sjodin A, Guo D, Sorhaug S, Bjermer L, Henriksson R, Hedman H. Dysregulated secretoglobin expression in human lung cancers. Lung Cancer 2003; 41:49-56; PMID:12826312; http://dx.doi.org/10.1016/S0169-5002(03)00126-0
41. Munakata K, Uemura M, Takemasa I, Ozaki M, Konno M, Nishimura J, Hata T, Mizushima T, Haraguchi N, Noura S, et al. SCGB2A1 is a novel prognostic marker for colorectal cancer associated with chemoresistance and radioresistance. Int J Oncol 2014; 44:1521-8; PMID:24585249
42. Aihara T, Fujiwara Y, Miyake Y, Okami J, Okada Y, Iwao K, Sugita Y, Tomita N, Sakon M, Shiozaki H, et al. Mammaglobin B gene as a novel marker for lymph node micrometastasis in patients with abdominal cancers. Cancer Lett 2000; 150:79-84; PMID:10755390; http://dx.doi.org/10.1016/S0304-3835(99)00378-X
43. Okami J, Dohno K, Sakon M, Iwao K, Yamada T, Yamamoto H, Fujiwara Y, Nagano H, Umeshita K, Matsuura N, et al. Genetic detection for micrometastasis in lymph node of biliary tract carcinoma. Clin Cancer Res 2000; 6:2326-32; PMID:10873083
44. Aihara T, Fujiwara Y, Ooka M, Sakita I, Tamaki Y, Monden M. Mammaglobin B as a novel marker for detection of breast cancer micrometastases in axillary lymph nodes by reverse transcription-polymerase chain reaction. Breast Cancer Res Treat 1999; 58:137-40; PMID:10674878; http://dx.doi.org/10.1023/A:1006335817889
45. Bergenheim AT, Henriksson R. Pharmacokinetics and pharmacodynamics of estramustine phosphate. Clin Pharmacokinet 1998; 34:163-72; PMID:9515186; http://dx.doi.org/10.2165/00003088-199834020-00004
46. Walz PH, Bjork P, Gunnarsson PO, Edman K, Hartley-Asp B. Differential uptake of estramustine phosphate metabolites and its correlation with the levels of estramustine binding protein in prostate tumor tissue. Clin Cancer Res 1998; 4:2079-84; PMID:9748122
47. Ravery V, Fizazi K, Oudard S, Drouet L, Eymard JC, Culine S, Gravis G, Hennequin C, Zerbib M. The use of estramustine phosphate in the modern management of advanced prostate cancer. BJU Int 2011; 108:1782-6; PMID:21756277; http://dx.doi.org/10.1111/j.1464-410X.2011.10201.x
48. Greathouse KL, Bredfeldt T, Everitt JI, Lin K, Berry T, Kannan K, Mittelstadt ML, Ho SM, Walker CL. Environmental estrogens differentially engage the histone methyltransferase EZH2 to increase risk of uterine tumorigenesis. Mol Cancer Res 2012; 10:546-57; PMID:22504913; http://dx.doi.org/10.1158/1541-7786.MCR-11-0605
49. Padmanabhan V, Siefert K, Ransom S, Johnson T, Pinkerton J, Anderson L, Tao L, Kannan K. Maternal bisphenol-A levels at delivery: A looming problem? J Perinatol 2008; 28:258-63; PMID:18273031; http://dx.doi.org/10.1038/sj.jp.7211913
50. Ozten N, Horton L, Lasano S, Bosland MC. Selenomethionine and a-tocopherol do not inhibit prostate carcinogenesis in the testosterone plus estradiol-treated NBL rat model. Cancer Prev Res 2010; 3:371-80; PMID:20179302; http://dx.doi.org/10.1158/1940-6207.CAPR-09-0152
51. Shappell SB, Thomas GV, Roberts RL, Herbert R, Ittmann MM, Rubin MA, Humphrey PA, Sundberg JP, Rozengurt N, Barrios R, et al. Prostate pathology of genetically engineered mice: definitions and classification. The consensus report from the Bar Harbor meeting of the Mouse Models of Human Cancer Consortium Prostate Pathology Committee. Cancer Res 2004; 64:2270-305; PMID:15026373; http://dx.doi.org/10.1158/0008-5472.CAN-03-0946
52. Hajkova P, el-Maarri O, Engemann S, Oswald J, Olek A, Walter J. DNA-methylation analysis by the bisulfiteassisted genomic sequencing method. Methods Mol Biol 2002; 200:143-54; PMID:11951649